Cargando…
Exenatide Use in the Management of Type 2 Diabetes Mellitus
Exenatide is a GLP-1 (glucagon-like peptide-1) agonist that has been approved in the UK for use in the management of Type 2 Diabetes Mellitus (T2DM) since 2006. It acts by increasing glucose-induced insulin release and by reducing glucagon secretion postprandially. It therefore increases insulin sec...
Autores principales: | Kyriacou, Angelos, Ahmed, Abu Baker |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033938/ https://www.ncbi.nlm.nih.gov/pubmed/27713366 http://dx.doi.org/10.3390/ph3082554 |
Ejemplares similares
-
Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary, Jason, et al.
Publicado: (2010) -
Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
por: Inaishi, Jun, et al.
Publicado: (2022) -
Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013) -
Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
por: Voukali, Maria, et al.
Publicado: (2014) -
Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus
por: Khan, Muhammad, et al.
Publicado: (2015)